More interestingly, EMT in the cisplatin-resistant gastric cancer cells could be abrogated by monoclonal antibody Herceptin, small molecular targeted drug CP724714, or small interfering RNAs (siRNAs) against HER2. This evidence concerns the gene ERBB2 and gastric cancer.